

CORRECTION

Open Access



Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

Alexandra Langlois¹, Marie-Hélène Lavergne², Hélène Leroux², Kerstin Killer², Pauline Azzano¹, Louis Paradis^{1,3}, Kathryn Samaan¹, Jonathan Lacombe-Barrios¹, Thomas Eiwegger⁴, Julia Upton⁴, Gordon Sussman⁵, Thomas Poder^{6,7}, Benoît Mâsse^{2,8}, Anne Des Roches^{1,2} and Philippe Bégin^{1,2,3*}

Correction to: *Allergy Asthma Clin Immunol* (2020) 16:25 <https://doi.org/10.1186/s13223-020-00419-z>

The names of Thomas Eiwegger, Julia Upton, Gordon Sussman and Thomas Poder were inadvertently omitted from the authorship of the original article [1]. Thomas Eiwegger, Julia Upton, Gordon Sussman and Thomas Poder had participated in meetings and exchanges regarding the trial design and their names are added to recognise their contribution to the conception of the protocol.

The full and correct authorship has been updated in the original article and included in the author list of this Correction article.

The 'Competing interests' section is also corrected here to read: The authors declare no conflict of interest related to the study. KS reports personal fees from Novartis outside the submitted work. TE reports grants from DBV technologies, Innovation fund Denmark, CIHR, and Regeneron and personal fees from ALK outside the submitted work. He serves as associate editor for *Allergy*. JU reports personal fees from Food Allergy

Canada, ALK-Abelló, Kaleo, and grants from Toronto SickKids Foundation, DBV technologies, Regeneron, and ALK-Abelló outside the submitted work. GS reports personal fees from Novartis, Aralez, CSL Behring, Sanofi, Pediapharm, GSK, Genentech, DBV technologies, Aimmune, Astrazeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Shire, Leopharma, Regeneron, mdBriefCase and grants from Novartis, GSK, Genentech, DBV technologies, Aimmune, CSL Behring, Astrazeneca, Stallergenes, Merck, Pfizer, Dyax, Biocryst, Greencross, Kendrion, Leo Pharma, Regeneron, Sanofi, Blueprint, ALK, Amgen, Cliantha outside the submitted work. ADR reports grants from Merck and ALK outside the submitted work. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.

Author details

¹ Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada. ² Centre Hospitalier Sainte-Justine Research Center, Montreal, QC, Canada. ³ Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1C5, Canada. ⁴ Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, ON, Canada. ⁵ Gordon Sussman Clinical Research, Toronto, ON, Canada. ⁶ Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC, Canada. ⁷ Research Center of the Institut Universitaire de

The original article can be found online at <https://doi.org/10.1186/s13223-020-00419-z>.

*Correspondence: philippe.begin@umontreal.ca

³ Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1C5, Canada

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Santé Mentale de Montréal, Montreal, QC, Canada. ⁸ School of Public Health, Université de Montréal, Montreal, QC, Canada.

Published online: 20 May 2020

Reference

1. Langlois A, Lavergne M-H, Leroux H, Killer K, Azzano P, Paradis L, Samaan K, Lacombe-Barrios J, Eiwegger T, Upton J, Sussman G, Poder T, Mâsse B,

Roches AD, Bégin P. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. *Allergy Asthma Clin Immunol*. 2020;16:25. <https://doi.org/10.1186/s13223-020-00419-z>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.